论文部分内容阅读
目的:观察2型糖尿病患者外周血单核细胞CD36的表达及罗格列酮对其表达的影响,探讨其可能的作用机制。方法:采用流式细胞仪测定2型糖尿病患者外周血单核细胞CD36的表达,并观察罗格列酮治疗后的变化;分析CD36与2型糖尿病各临床指标间的关系。结果:2型糖尿病组患者单核细胞CD36表达明显高于正常对照组(745.9±281.3vs406.3±80.2,P<0.01);动脉粥样硬化组CD36表达明显高于无动脉粥样硬化组(878.2±296.1vs584.2±148.3,P<0.01)。罗格列酮治疗后,患者单核细胞CD36表达、空腹血糖(FBG)、餐后血糖(PBG)、HbA1c、空腹胰岛素(FIN)、餐后胰岛素(PIN)、胰岛素抵抗程度(HOMA-IR)均降低,与治疗前、安慰剂组均有统计学差异(P<0.05或P<0.01)。糖尿病患者单核细胞CD36表达与FBG(r=0.55,P<0.05)、HbA1c(r=0.62,P<0.01)、HOMA-IR(r=0.64,P<0.01)正相关,与PBG、FIN、PIN无明显相关。结论:罗格列酮可能通过有效控制血糖、降低胰岛素抵抗等途径来降低2型糖尿病患者外周血单核细胞CD36的表达。
Objective: To observe the expression of CD36 in peripheral blood mononuclear cells and the effect of rosiglitazone on the expression of CD36 in type 2 diabetic patients and to explore its possible mechanism. Methods: The expression of CD36 in peripheral blood mononuclear cells of type 2 diabetic patients was measured by flow cytometry. The changes of CD36 expression in the peripheral blood mononuclear cells of type 2 diabetic patients were observed. The relationship between CD36 and various clinical indicators of type 2 diabetes mellitus was analyzed. Results: The expression of CD36 in monocytes in type 2 diabetes mellitus group was significantly higher than that in control group (745.9 ± 281.3 vs 406.3 ± 80.2, P <0.01). The expression of CD36 in atherosclerosis group was significantly higher than that in atherosclerosis group 878.2 ± 296.1 vs 584.2 ± 148.3, P <0.01). After rosiglitazone treatment, CD36 expression, FBG, PBG, HbA1c, FIN, PIN, HOMA-IR, Were lower than before treatment, placebo group were statistically significant (P <0.05 or P <0.01). The expression of CD36 in monocytes of diabetic patients was positively correlated with FBG (r = 0.55, P <0.05), HbA1c (r = 0.62, P <0.01) and HOMA-IR PIN is not significantly related. Conclusion: Rosiglitazone may reduce the expression of CD36 on peripheral blood mononuclear cells in type 2 diabetic patients through effective control of blood glucose and insulin resistance.